ABVC Biopharma Inc
NASDAQ:ABVC
ABVC Biopharma Inc
Net Income (Common)
ABVC Biopharma Inc
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
ABVC Biopharma Inc
NASDAQ:ABVC
|
Net Income (Common)
-$10.5m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-53%
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Income (Common)
$6.7B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
3%
|
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Net Income (Common)
-$440.2m
|
CAGR 3-Years
20%
|
CAGR 5-Years
10%
|
CAGR 10-Years
-17%
|
|
Karuna Therapeutics Inc
NASDAQ:KRTX
|
Net Income (Common)
-$433.7m
|
CAGR 3-Years
-85%
|
CAGR 5-Years
-90%
|
CAGR 10-Years
N/A
|
|
Moderna Inc
NASDAQ:MRNA
|
Net Income (Common)
-$4.7B
|
CAGR 3-Years
-85%
|
CAGR 5-Years
-64%
|
CAGR 10-Years
N/A
|
|
Sarepta Therapeutics Inc
NASDAQ:SRPT
|
Net Income (Common)
$17m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is ABVC Biopharma Inc's Net Income (Common)?
Net Income (Common)
-10.5m
USD
Based on the financial report for Dec 31, 2023, ABVC Biopharma Inc's Net Income (Common) amounts to -10.5m USD.
What is ABVC Biopharma Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-53%
Over the last year, the Net Income (Common) growth was 36%. The average annual Net Income (Common) growth rates for ABVC Biopharma Inc have been -2% over the past three years , -14% over the past five years , and -53% over the past ten years .